Log in
Enquire now
‌

US Patent 10377769 Benzopiperazine compositions as BET bromodomain inhibitors

Patent 10377769 was granted and assigned to FORMA Therapeutics on August, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
FORMA Therapeutics
FORMA Therapeutics
Current Assignee
FORMA Therapeutics
FORMA Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10377769
Date of Patent
August 13, 2019
Patent Application Number
16029166
Date Filed
July 6, 2018
Patent Citations Received
‌
US Patent 11028058 Heterocyclic compounds as adenosine antagonists
‌
US Patent 11584756 Heterocyclic compounds as BET inhibitors
‌
US Patent 11306071 Heterocyclic compounds as adenosine antagonists
‌
US Patent 11254670 1,8-naphthyridinone compounds and uses thereof
‌
US Patent 10611750 Tetrahydroquinoline compositions as bet bromodomain inhibitors
‌
US Patent 10703764 Benzopiperazine compositions as BET bromodomain inhibitors
‌
US Patent 10793561 1,8-naphthyridinone compounds and uses thereof
Patent Primary Examiner
‌
D Margaret M Seaman
Patent abstract

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I):

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10377769 Benzopiperazine compositions as BET bromodomain inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.